Toleranzia AB announced that the Company has been awarded a grant from Vinnova for a project aimed at developing a new unique disease-specific treatment for ANCA vasculitis. The project is awarded a total of SEK 2.9 million, which will be distributed among several grant recipients, of which Toleranzia is awarded SEK 1.7 million. The grant is awarded by Vinnova with financial support from Medtech4Heath and Swelife within the framework of the call "Swelife and Medtech4Health - Collaborative project for better health in the fall of 2022".

Toleranzia will run the project together with Lund University's Kidney Research Lab, Region Skåne and SciCross AB. The project runs for two years starting from April 3, 2023.